Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes

Next Previous
X
Search
Trial Profile

Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin detemir
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms Onset 1
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 01 Jun 2019 Post hoc analysis of Onset 1 and Onset 8 trial published in the Diabetes Therapy.
    • 07 Nov 2018 Results of a post hoc analysis of NCT01618188, NCT02003677, NCT01934712, NCT02568280 and NCT01831765 assessing the PK of fast-acting Insulin Aspart versus free Insulin Aspart, published in the Clinical Pharmacokinetics
    • 26 Jun 2018 Results investigating hypoglycemia across two double-blind, treat-to-target, randomized trials (NCT01831765; NCT02500706) presented at the 78th Annual Scientific Sessions of the American Diabetes Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top